{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:11:12Z","timestamp":1793193072006,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JJ9101"],"award-info":[{"award-number":["2024JJ9101"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.arr.2024.102595","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:03:27Z","timestamp":1732291407000},"page":"102595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Disease-modifying therapies for Alzheimer\u2019s disease: Clinical trial progress and opportunity"],"prefix":"10.1016","volume":"103","author":[{"given":"Yujie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6773-7790","authenticated-orcid":false,"given":"Shilin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2024.102595_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00415-011-6128-4","article-title":"Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia","volume":"259","author":"Ahmed","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/bem.20211","article-title":"Modulation of learning and hippocampal, neuronal plasticity by repetitive transcranial magnetic stimulation (rTMS)","volume":"27","author":"Ahmed","year":"2006","journal-title":"Bioelectromagnetics"},{"key":"10.1016\/j.arr.2024.102595_bib3","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1074\/jbc.RA119.012517","article-title":"Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau","volume":"295","author":"Ait-Bouziad","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2024.102595_bib4","unstructured":"Alzamend, 2023. Alzamend Neuro Announces the Initiation of a Phase I\/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer\u2019s Type. Available from: https:\/\/ir.alzamend.com\/news-events\/press-releases\/detail\/53. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib5","unstructured":"Alzforum, 2019. ASOs: Wave of the Future in Alzheimer\u2019s Therapeutics? Available from: https:\/\/www.alzforum.org\/news\/conference-coverage\/asos-wave-future-alzheimers-therapeutics. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/STROKEAHA.121.036948","article-title":"Neuroinflammation, stem cells, and stroke","volume":"53","author":"Anthony","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.arr.2024.102595_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res"},{"key":"10.1016\/j.arr.2024.102595_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148368","article-title":"A review of the advances, insights, and prospects of gene therapy for Alzheimer's disease: a novel target for therapeutic medicine","volume":"912","author":"Ataei","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.arr.2024.102595_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2639","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.arr.2024.102595_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archneurol.2009.307","article-title":"Effects of aerobic exercise on mild cognitive impairment: a controlled trial","volume":"67","author":"Baker","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1001\/jama.288.18.2271","article-title":"Effects of cognitive training interventions with older adults: a randomized controlled trial","volume":"288","author":"Ball","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.arr.2024.102595_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.nbd.2016.03.027","article-title":"Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned?","volume":"97","author":"Bartus","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.arr.2024.102595_bib13","article-title":"Donepezil for dementia due to Alzheimer's disease","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.arr.2024.102595_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.brs.2011.06.006","article-title":"Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease","volume":"5","author":"Boggio","year":"2012","journal-title":"Brain Stimul."},{"key":"10.1016\/j.arr.2024.102595_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's Disease","volume":"55","author":"Cebers","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.arr.2024.102595_bib18","unstructured":"Alzforum, 2022. In Small Trial, Gene Therapy Spurs ApoE2 Production. Available from: https:\/\/www.alzforum.org\/news\/conference-coverage\/small-trial-gene-therapy-spurs-apoe2-production. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib19","unstructured":"Chinese Clinical Trial Registry, 2020. A single center, randomized, double blind, placebo parallel controlled trial for human neural stem cells (ANGE S004) in the treatment of Alzheimer's disease.Available from: https:\/\/www.chictr.org.cn\/showproj.html?proj=47760. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.2507","article-title":"Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease","volume":"31","author":"Cho","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.arr.2024.102595_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03410-8","article-title":"Identification of potential biomarkers related to mesenchymal stem cell response in patients with Alzheimer's disease","volume":"14","author":"Choi","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.arr.2024.102595_bib22","unstructured":"Chinese Clinical Trial Registry, 2020. Effect of human neural stem cells on patients with moderate to severe early-onset Alzheimer's disease clinical study on safety and effectiveness.Available from: https:\/\/www.chictr.org.cn\/showproj.html?proj=61608. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fcell.2020.00541","article-title":"Plasma BDNF levels following transcranial direct current stimulation allow prediction of synaptic plasticity and memory deficits in 3\u00d7Tg-AD Mice","volume":"8","author":"Cocco","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.arr.2024.102595_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tips.2017.07.005","article-title":"Early and Late CNS Inflammation in Alzheimer's disease: two extremes of a continuum?","volume":"38","author":"Cuello","year":"2017","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.arr.2024.102595_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","article-title":"The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study","volume":"17","author":"van der Lee","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cpt.2954","article-title":"Physician perspectives on the food and drug administration's decision to grant accelerated approval to aducanumab for Alzheimer's Disease","volume":"114","author":"Dhruva","year":"2023","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.arr.2024.102595_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41551-021-00759-0","article-title":"Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice","volume":"6","author":"Duan","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.arr.2024.102595_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11010120","article-title":"Stem cell therapy for Alzheimer's disease: a scoping review for 2017-2022","volume":"11","author":"Duan","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.arr.2024.102595_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13287-017-0567-5","article-title":"Alzheimer's disease, dementia, and stem cell therapy","volume":"8","author":"Duncan","year":"2017","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.arr.2024.102595_bib30","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2016.91","article-title":"Vanutide Cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer's disease: amyloid imaging positron emission tomography and safety results from a phase 2 study","author":"van Dyck","year":"2016","journal-title":"J. Prev. Alzheimers Dis. 3, 75-84"},{"key":"10.1016\/j.arr.2024.102595_bib31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2024.102595_bib32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2174\/1871527313666140806124850","article-title":"Toll-like receptors in Alzheimer's disease: a therapeutic perspective","volume":"13","author":"Gambuzza","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.arr.2024.102595_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","article-title":"Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease","volume":"577","author":"Gate","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.arr.2024.102595_bib34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.arr.2024.102595_bib35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2024.102595_bib36","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (\u03b2-secretase) inhibitors for the treatment of Alzheimer's disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.arr.2024.102595_bib37","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102595_bib38","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.brs.2015.07.044","article-title":"Rapid modulation of protein expression in the rat hippocampus following deep brain stimulation of the fornix","volume":"8","author":"Gondard","year":"2015","journal-title":"Brain Stimul."},{"key":"10.1016\/j.arr.2024.102595_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement (N. Y"},{"key":"10.1016\/j.arr.2024.102595_bib40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer's disease treated with escalating doses for up to 133 weeks","volume":"76","author":"Guthrie","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-Secretase BACE1 in Alzheimer's Disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2024.102595_bib42","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00018-007-7220-x","article-title":"Tauopathies","volume":"64","author":"Hern\u00e1ndez","year":"2007","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.arr.2024.102595_bib43","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1523\/JNEUROSCI.0236-16.2016","article-title":"Shaping intrinsic neural oscillations with periodic stimulation","volume":"36","author":"Herrmann","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib44","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/j.neubiorev.2013.09.002","article-title":"Deep brain stimulation in dementia-related disorders","volume":"37","author":"Hescham","year":"2013","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.arr.2024.102595_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of alz-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.arr.2024.102595_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1126\/science.1179555","article-title":"CRISPR\/Cas, the immune system of bacteria and archaea","volume":"327","author":"Horvath","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102595_bib47","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1002\/jcb.27202","article-title":"Stem cell- and gene-based therapies as potential candidates in Alzheimer's therapy","volume":"119","author":"Hosseini","year":"2018","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.arr.2024.102595_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jneumeth.2016.03.017","article-title":"Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells","volume":"266","author":"Hu","year":"2016","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.arr.2024.102595_bib49","unstructured":"The U.S. Food and Drug Administration, 2024. FDA approves treatment for adults with Alzheimer\u2019s disease. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","article-title":"Tau and neurodegenerative disease: the story so far","volume":"12","author":"Iqbal","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib51","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1093\/nar\/15.9.3917","article-title":"Nucleotide sequence of the meso-diaminopimelate D-dehydrogenase gene from Corynebacterium glutamicum","volume":"15","author":"Ishino","year":"1987","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.arr.2024.102595_bib52","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102595_bib53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current status of clinical trials on tau immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2024.102595_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2024.102595_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/sci-2021-063","article-title":"Advances in stem cell therapy in Alzheimer's disease: a comprehensive clinical trial review","volume":"9","author":"Karvelas","year":"2022","journal-title":"Stem Cell Invest."},{"key":"10.1016\/j.arr.2024.102595_bib56","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2010.493872","article-title":"Bapineuzumab","volume":"10","author":"Kerchner","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.arr.2024.102595_bib57","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3233\/JAD-200026","article-title":"Feasibility and efficacy of intra-arterial administration of embryonic stem cell derived-mesenchymal stem cells in animal model of Alzheimer's disease","volume":"76","author":"Kim","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13195-021-00897-2","article-title":"Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial","volume":"13","author":"Kim","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102595_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-200219","article-title":"Mesenchymal stem cell therapy and aAlzheimer's disease: current status and future Perspectives","volume":"77","author":"Kim","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102595_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000486546","article-title":"A Systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia","volume":"45","author":"Knight","year":"2018","journal-title":"Dement Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2024.102595_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","article-title":"Elucidating the A\u03b242 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical methods, pharmacokinetic and clinical data","volume":"31","author":"Kocis","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2024.102595_bib63","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/brain\/awn008","article-title":"Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity.","volume":"131","author":"Kotilinek","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.arr.2024.102595_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.arr.2015.04.006","article-title":"Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies","volume":"22","author":"Kuiper","year":"2015","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2024.102595_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.31887\/DCNS.2019.21.1\/nlautenschlager","article-title":"Physical activity for cognitive health: what advice can we give to older adults with subjective cognitive decline and mild cognitive impairment?","volume":"21","author":"Lautenschlager","year":"2019","journal-title":"Dialog-. Clin. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.22089","article-title":"A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease","volume":"68","author":"Laxton","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib67","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/nprot.2013.155","article-title":"Object recognition test in mice","volume":"8","author":"Leger","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.arr.2024.102595_bib68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-8-36","article-title":"Immunotherapy for Alzheimer's disease: hoops and hurdles","volume":"8","author":"Lemere","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2024.102595_bib69","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1128\/MCB.00544-13","article-title":"P2Y4 receptor-mediated pinocytosis contributes to amyloid beta-induced self-uptake by microglia","volume":"33","author":"Li","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.arr.2024.102595_bib70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41594-020-0505-6","article-title":"Kinetic fingerprints differentiate the mechanisms of action of anti-A\u03b2 antibodies","volume":"27","author":"Linse","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.arr.2024.102595_bib71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4252\/wjsc.v12.i8.787","article-title":"Stem cell therapy for Alzheimer's disease","volume":"12","author":"Liu","year":"2020","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.arr.2024.102595_bib72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nbt.2565","article-title":"Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits","volume":"31","author":"Liu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.arr.2024.102595_bib73","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2024.102595_bib74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/ADR-210296","article-title":"Phase II (NAVIGATE-AD study) Results of LY3202626 effects on patients with mild Alzheimer's disease dementia","volume":"5","author":"Lo","year":"2021","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.arr.2024.102595_bib75","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.neuron.2013.01.020","article-title":"Probing and regulating dysfunctional circuits using deep brain stimulation","volume":"77","author":"Lozano","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2024.102595_bib76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JAD-160017","article-title":"A Phase II Study of fornix deep brain stimulation in mild Alzheimer's disease","volume":"54","author":"Lozano","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib77","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41582-018-0128-2","article-title":"Deep brain stimulation: current challenges and future directions","volume":"15","author":"Lozano","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.803894","article-title":"Application of CRISPR\/Cas9 in Alzheimer's Disease","volume":"15","author":"Lu","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib79","article-title":"Genetic associations between modifiable risk factors and Alzheimer disease","volume":"6","author":"Luo","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.arr.2024.102595_bib80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","article-title":"Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice","volume":"102","author":"MacPherson","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102595_bib81","first-page":"370","article-title":"Alzheimer disease: NSAIDs protect neurons and preserve memory in a mouse model of AD","volume":"12","author":"Malkki","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib82","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev-cellbio-100913-013116","article-title":"The nature of embryonic stem cells","volume":"30","author":"Martello","year":"2014","journal-title":"Annu Rev. Cell Dev. Biol."},{"key":"10.1016\/j.arr.2024.102595_bib83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/wsbm.100","article-title":"Maintenance and differentiation of neural stem cells","volume":"3","author":"Massirer","year":"2011","journal-title":"Wiley Inter. Rev. Syst. Biol. Med"},{"key":"10.1016\/j.arr.2024.102595_bib84","doi-asserted-by":"crossref","first-page":"16507","DOI":"10.1523\/JNEUROSCI.3647-11.2011","article-title":"Robust central reduction of amyloid-\u03b2 in humans with an orally available, non-peptidic \u03b2-secretase inhibitor","volume":"31","author":"May","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib85","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","article-title":"The potent BACE1 inhibitor LY2886721 elicits robust central A\u03b2 pharmacodynamic responses in mice, dogs, and humans","volume":"35","author":"May","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102595_bib87","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2024.102595_bib88","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diff.2009.06.005","article-title":"Transplantation of primed or unprimed mouse embryonic stem cell-derived neural precursor cells improves cognitive function in Alzheimerian rats","volume":"78","author":"Moghadam","year":"2009","journal-title":"Differentiation"},{"key":"10.1016\/j.arr.2024.102595_bib89","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase ii study of the safety and efficacy of semorinemab in participants with mild-to-moderate alzheimer disease: Lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102595_bib90","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jalz.2014.11.009","article-title":"MIND diet associated with reduced incidence of Alzheimer's disease","volume":"11","author":"Morris","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2024.102595_bib91","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/nan.12319","article-title":"Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP\/PS1 Alzheimer mice","volume":"43","author":"Naaldijk","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.arr.2024.102595_bib92","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline","volume":"283","author":"N\u00e4slund","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.arr.2024.102595_bib93","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.arr.2024.102595_bib94","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1093\/brain\/awad239","article-title":"Neurophysiological mechanisms of deep brain stimulation across spatiotemporal resolutions","volume":"146","author":"Neumann","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.arr.2024.102595_bib95","unstructured":"Biogen, 2023. New Data Presented at AD\/PD\u2122 2023 Show Biogen\u2019s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer\u2019s Disease.Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-data-presented-adpdtm-2023-show-biogens-biib080-mapt-aso. Accessed 7 Oct 2024."},{"key":"10.1016\/j.arr.2024.102595_bib96","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2024.102595_bib97","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.brs.2023.04.001","article-title":"The impact of gamma transcranial alternating current stimulation (tACS) on cognitive and memory processes in patients with mild cognitive impairment or Alzheimer's disease: a literature review","volume":"16","author":"Nissim","year":"2023","journal-title":"Brain Stimul."},{"key":"10.1016\/j.arr.2024.102595_bib98","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib99","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2006.12.008","article-title":"BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP\/PS1 transgenic mice","volume":"26","author":"Ohno","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2024.102595_bib100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/0956797613499592","article-title":"The impact of sustained engagement on cognitive function in older adults: the synapse project","volume":"25","author":"Park","year":"2014","journal-title":"Psychol. Sci."},{"key":"10.1016\/j.arr.2024.102595_bib102","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121229","article-title":"Transcriptional activation with Cas9 activator nanocomplexes rescues Alzheimer's disease pathology","volume":"279","author":"Park","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.arr.2024.102595_bib104","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JAD-180212","article-title":"Deep brain stimulation of the memory circuit: improving cognition in Alzheimer's Disease","volume":"64","author":"Posporelis","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00702-012-0902-z","article-title":"Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study","volume":"120","author":"Rabey","year":"2013","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.arr.2024.102595_bib106","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib107","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102595_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1011225","article-title":"Mesenchymal stromal cells for the treatment of Alzheimer's disease: strategies and limitations","volume":"15","author":"Regmi","year":"2022","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2024.102595_bib110","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","article-title":"Nerve growth factor: early studies and recent clinical trials","volume":"16","author":"Rocco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2024.102595_bib111","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCO.0000000000000779","article-title":"Social health, social reserve and dementia","volume":"35","author":"Sachdev","year":"2022","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.arr.2024.102595_bib112","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/jcph.950","article-title":"BACE1 Inhibitor Lanabecestat (AZD3293) in a phase 1 study of healthy japanese subjects: pharmacokinetics and effects on plasma and cerebrospinal fluid a\u03b2 peptides","volume":"57","author":"Sakamoto","year":"2017","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.arr.2024.102595_bib113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib114","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ana.20854","article-title":"Mediterranean diet and risk for Alzheimer's disease","volume":"59","author":"Scarmeas","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib115","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2024.102595_bib116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arr.2024.102595_bib117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2024.102595_bib118","first-page":"247","article-title":"Development review of the BACE1 inhibitor lanabecestat (AZD3293\/LY3314814)","volume":"4","author":"Sims","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib119","doi-asserted-by":"crossref","first-page":"10893","DOI":"10.1073\/pnas.96.19.10893","article-title":"Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy","volume":"96","author":"Smith","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2024.102595_bib120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's Disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102595_bib121","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/ern.11.56","article-title":"Diet and Alzheimer's disease risk factors or prevention: the current evidence","volume":"11","author":"Solfrizzi","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.arr.2024.102595_bib122","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib123","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2024.102595_bib124","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.1081297","article-title":"Inactivation of TNF signaling by rationally designed dominant-negative TNF variants","volume":"301","author":"Steed","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.arr.2024.102595_bib125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1744-1609.2010.00150.x","article-title":"Cognitive leisure activities and their role in preventing dementia: a systematic review","volume":"8","author":"Stern","year":"2010","journal-title":"Int J. Evid. Based Health"},{"key":"10.1016\/j.arr.2024.102595_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101318","article-title":"Therapy for Alzheimer's disease: missing targets and functional markers?","volume":"68","author":"Stoiljkovic","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2024.102595_bib127","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene Therapy for Neurodegenerative Diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102595_bib128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-018-07971-8","article-title":"CRISPR\/Cas9 editing of APP C-terminus attenuates \u03b2-cleavage and promotes \u03b1-cleavage","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2024.102595_bib129","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.arr.2024.102595_bib130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib131","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3171\/JNS\/2008\/108\/01\/0132","article-title":"The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation","volume":"108","author":"Toda","year":"2008","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.arr.2024.102595_bib132","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1097\/TP.0000000000001426","article-title":"Clinical application of pluripotent stem cells: an alternative cell-based therapy for treating liver diseases?","volume":"100","author":"Tolosa","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.arr.2024.102595_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101108","article-title":"Exercise benefits on Alzheimer's disease: State-of-the-science","volume":"62","author":"Valenzuela","year":"2020","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2024.102595_bib134","article-title":"Immunotherapies for Alzheimer's disease-a review","volume":"10","author":"Valiukas","year":"2022","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.arr.2024.102595_bib135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2024.102595_bib136","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2024.102595_bib137","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tics.2013.08.001","article-title":"Bridging animal and human models of exercise-induced brain plasticity","volume":"17","author":"Voss","year":"2013","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.arr.2024.102595_bib138","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.arr.2024.102595_bib139","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","article-title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model","volume":"160","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.arr.2024.102595_bib140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2024.102595_bib141","first-page":"236","article-title":"Preclinical and Clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2024.102595_bib142","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.stemcr.2015.09.010","article-title":"ESC-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with alzheimer's disease in mouse models","volume":"5","author":"Yue","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.arr.2024.102595_bib143","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13287-022-03231-1","article-title":"Neural stem\/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Stem Cell Res Ther."},{"key":"10.1016\/j.arr.2024.102595_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.618171","article-title":"Gene therapy for neurodegenerative disease: clinical potential and directions","volume":"14","author":"Zhu","year":"2021","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2024.102595_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/life12091440","article-title":"The immune system as a therapeutic target for Alzheimer's disease","volume":"12","author":"Zieneldien","year":"2022","journal-title":"Life"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724004136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724004136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:26:23Z","timestamp":1733729183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163724004136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":145,"alternative-id":["S1568163724004136"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2024.102595","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying therapies for Alzheimer\u2019s disease: Clinical trial progress and opportunity","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2024.102595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102595"}}